Excellent response to olaparib in metastatic HR-positive, HER2-negative breast cancer with BRIP1 mutation

Ann Oncol. 2023 Mar;34(3):315-318. doi: 10.1016/j.annonc.2023.01.012.

Authors

D Kwapisz¹, B Verret², C Garcia³, F André⁴

Affiliations

¹ Institut Gustave Roussy, Villejuif, France; Centre of Postgraduate Medical Education, Department of Biochemistry and Molecular Biology, Warsaw, Poland. Electronic address: dmkwapisz@gmail.com.
² Division of Medical Oncology, Institut Gustave Roussy, Villejuif, France.
³ Nuclear Medicine Department, Gustave Roussy cancer campus, Villejuif, France.
⁴ Institut Gustave Roussy, INSERM U981, Université Paris Saclay, Villejuif, France.

PMID: 36813328
DOI: 10.1016/j.annonc.2023.01.012

No abstract available

Publication types

Letter

MeSH terms

Breast Neoplasms* / pathology
Female
Humans
Mutation
Phthalazines
Piperazines
Receptor, ErbB-2 / genetics

Substances

olaparib
Phthalazines
Piperazines
Receptor, ErbB-2